Featured Content

Digital
Deep Dive Digital Health 2023

Deep Dive: Digital Health 2023

In this issue of Deep Dive, AXON’s Silvia De Carvalho details how generative AI is ushering in a new era of expedited, data-driven clinical research, experts from Research Partnership discu

Newsletters and Deep Dive
digital magazine

Latest News

Views & Analysis

Deep Dive

Digital
Deep Dive Digital Health 2023

Deep Dive: Digital Health 2023

In this issue of Deep Dive, AXON’s Silvia De Carvalho details how generative AI is ushering in a new era of expedited, data-driven clinical research, experts from Research Partnership discu

Patients
Intellectual property: Striking the balance

Intellectual property: Striking the balance

For many spin-outs and start-ups in the pharmaceutical space, a key step in getting their science into patients is teaming up with a larger pharmaceutical company.

White Papers & Webinar

Podcasts & Video

R&D
pharmaphorum podcast episode 101a

Reducing the stigma attached to psychedelics

It’s no secret that 2023 has been a year for a shift in thinking when it comes to psychedelics, in particular as pertains to their use for hard-to-treat or treatment resistant mental health

Partner Content

R&D
3rd Next Generation RNA Therapeutics Summit
Partner Content

3rd Next Generation RNA Therapeutics Summit

Accelerate Next Generation RNAs into Safe & Effective Clinical Candidates with Therapeutic Potentials Across All Diseases by Overcoming Quality, Stability, & Large-Scale Manufacturi

R&D
6th Chronic Kidney Disease Drug Development Summit
Partner Content

6th Chronic Kidney Disease Drug Development Summit

The surge of clinical breakthroughs in SGLT2s, GLP-1s and ERAs for CKD, significant advancements to strengthen proteinuria and GFR slope as surrogates for long-term outcomes, and a wave of

R&D
5th Targeted Radiopharmaceuticals Summit Europe 2023
Partner Content

5th Targeted Radiopharmaceuticals Summit Europe 2023

With the recent double whammy of Bayer and Novartis both strategically investing in Bicycle Therapeutics to develop radioconjugates for oncology targets; mergers, acquisitions and collabora